Bevacizumab (Avastin) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by ...
Jun 6, 2011
0
0
Stage III colon cancer patients in the general population who receive adjuvant treatment for the disease have an improved rate of survival when oxaliplatin is added to 5-fluorouracil (5FU), according to a study published ...
Jan 20, 2012
0
0
(HealthDay)—Chemotherapy at the start of hormone therapy can extend the lives of men with prostate cancer that has spread beyond the gland, a new study finds.
Aug 6, 2015
0
32
An immunotherapy drug called pembrolizumab has been shown to significantly reduce disease recurrence in patients with the most aggressive type of breast cancer, according to results from a phase III clinical trial led by ...
Feb 10, 2022
0
13
The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress ...
Oct 8, 2016
0
4
Osteosarcoma patients with tumors that haven't responded well to the standard chemotherapy regimen have unimproved outcomes and more side effects when given two additional drugs, a large international trial has found.
Aug 26, 2016
0
0
Findings from the Garvan Institute of Medical Research reveal a new Australian drug that targets scar-like 'fibrotic' tissue within tumors shows promise for treating pancreatic ductal adenocarcinoma, one of the most aggressive ...
Aug 29, 2023
0
32
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
Jan 17, 2018
0
20
Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who ...
Dec 8, 2011
0
0
A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published in Clinical Cancer Research.
Apr 3, 2012
0
0
